Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older.
- People who are willing and able to sign a consent form for the trial.
- People who have metastatic breast cancer, or a hereditary cancer syndrome with a moderate to high lifetime risk of breast cancer, and who are either treated or followed at UZ Leuven, or treated at another hospital and referred to UZ Leuven specifically for this trial.
For specific parts of the trial, additional criteria apply:
- ILC substudy: People who have a confirmed history of a specific type of breast cancer called invasive lobular carcinoma (ILC), confirmed by tissue testing.
- IBC substudy: People who have a history of inflammatory breast cancer (IBC), meeting specific clinical criteria including rapid onset of breast redness, swelling, skin changes and/or warmth, lasting no more than 6 months, with redness covering at least one-third of the breast, and confirmed by tissue testing (confirm with trial site).
- Hereditary cancer syndrome substudy: People who have a confirmed inherited gene change linked to a moderate to high lifetime risk of breast cancer (for example, changes in genes such as BRCA1, BRCA2, CHEK2, TP53, or PALB2), and who have at least one active cancer lesion of any type at the time of joining.
Who may not be able to join:
- People who have a transmissible (infectious) disease that could pose a health risk to researchers or those handling patient samples. This includes but is not limited to: HIV, active hepatitis C, encephalitis of unknown cause, Creutzfeldt-Jakob disease, rabies, active malaria, active tuberculosis, or active COVID-19 (SARS-CoV-2).
- People whose circumstances could make it difficult to carry out the study procedures within the required timeframes — for example, living far from UZ Leuven, living outside of Belgium, or situations where it would not be possible to notify the medical team quickly enough in the event of death.
- ILC and IBC substudies only: People who have been diagnosed with any cancer other than breast cancer in the 5 years before joining. Exceptions are made for certain skin cancers (basal cell carcinoma or squamous cell carcinoma of the skin) and early-stage cervical cancer confined to the surface (in situ cervical carcinoma).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 003216336539
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percentage of patients consenting to participate in the pilot phase; Median time elapsed between moment of death and start of the autopsy; Median time elapsed between collection of first and last sample; Percentage of metastatic organs sampled; Percentage of samples with sufficient quality of DNA extracted; Percentage of samples with sufficient quality of RNA extracted
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.